Özet
Gut ve psoriatik artrit (PsA) birlikteliği uzun süredir bilinmekle birlikte, ortak komorbiditeler ve benzer klinik fenotiplere yönelik artan farkındalık nedeniyle son yıllarda klinik pratikte daha sık karşılaşılmaktadır. Bu durum, tanı sürecinde ayrıştırma güçlükleri ve tedavi stratejilerinin bireyselleştirilmesi açısından çeşitli zorluklara yol açmaktadır. Epidemiyolojik çalışmalar hem kutanöz psoriasisli hem de PsA’lı hastalarda gut gelişme riskinin arttığını göstermektedir. PsA ve gut, ortak risk faktörlerine sahip olup, bu durum altta yatan ve birbiriyle sıkı bir şekilde bağlantılı patofizyolojik mekanizmaların varlığını düşündürmektedir. Bu derlemede, gut ve PsA arasındaki örtüşme; paylaşılan klinik özellikler ortak enflamatuvar süreçler ve eşlik eden komorbiditeler bağlamında ele alınmakta ve yeni bir “örtüşen sendrom” olarak “Psout” adıyla yeni bir tanımlama tartışılmaktadır. Bu yeni yaklaşım, klinik pratiğe tanı doğruluğu ve tedavi optimizasyonu açısından anlamlı katkılar sunabilir.
Anahtar Kelimeler:
Psöriasis, psöriatik artrit, hiperürisemi, gut, psout
Kaynaklar
1
Sherri A, Mortada MM, Makowska J, Sokolowska M, Lewandowska-Polak A. Understanding the interplay between psoriatic arthritis and gout: “Psout”. Rheumatol Int. 2024;44:2699-709.
2
Yokose C, McCormick N, Lu N, et al. Trends in prevalence of gout among US Asian adults, 2011-2018. JAMA Netw Open. 2023;6:e239501.
3
Rai SK, Aviña-Zubieta JA, McCormick N, et al. The rising prevalence and incidence of gout in British Columbia, Canada: population-based trends from 2000 to 2012. Semin Arthritis Rheum. 2017;46:451-6.
4
Tu F-Y, Lin G-T, Lee S-S, Tung Y-C, Tu H-P, Chiang H-C. Prevalence of gout with comorbidity aggregations in southern Taiwan. Joint Bone Spine. 2015;82:45-51.
5
Winnard D, Wright C, Taylor WJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford). 2012;51:901-9.
6
Mease PJ, Karki C, Palmer JB, et al. Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the corrona psoriatic arthritis/spondyloarthritis registry. Arthritis Care Res (Hoboken). 2017;69:1692-9.
7
Haddad A, Elkayam PC, Stein N, et al. Epidemiological trends in psoriatic arthritis: a comprehensive population-based study. Arthritis Res Ther. 2024;26:108.
8
Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125:679-87.e1.
9
Lai TL, Yim CW, Wong PY, Leung MC, Ng WL. Hyperuricemia in Asian psoriatic arthritis patients. Int J Rheum Dis. 2018;21:843-9.
10
Merola JF, Wu S, Han J, Choi HK, Qureshi AA. Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis. 2015;74:1495-500.
11
Chandratre P, Sabido-Sauri R, Zhao SS, Abhishek A. Gout, hyperuricemia and psoriatic arthritis: an evolving conundrum. Curr Rheumatol Rep. 2025;27:22.
12
Felten R, Duret P-M, Gottenberg J-E, Spielmann L, Messer L. At the crossroads of gout and psoriatic arthritis: “psout”. Clin Rheumatol. 2020;39:1405-13.
13
Tripolino C, Ciaffi J, Ruscitti P, Giacomelli R, Meliconi R, Ursini F. Hyperuricemia in psoriatic arthritis: epidemiology, pathophysiology, and clinical implications. Front Med. 2021;8:737573.
14
Eleftheriadis T, Pissas G, Sounidaki M, et al. Urate crystals directly activate the T-cell receptor complex and induce T-cell proliferation. Biomed Reports. 2017;7:365-9.
15
Schauer C, Janko C, Munoz LE, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med. 2014;20:511-7.
16
Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143:499-516.
17
Lea WAJ, Curtis AC, Bernstein IA. Serum uric acid levels in psoriasis. J Invest Dermatol. 1958;31:269-71.
18
Li X, Miao X, Wang H, et al. Association of serum uric acid levels in psoriasis: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95:e3676.
19
Hu SC-S, Lin C-L, Tu H-P. Association between psoriasis, psoriatic arthritis and gout: a nationwide population-based study. J Eur Acad Dermatol Venereol. 2019;33:560-7.
20
Tsuruta N, Imafuku S, Narisawa Y. Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. J Dermatol. 2017;44:1349-52.
21
Bruce IN, Schentag CT, Gladman DD. Hyperuricemia in psoriatic arthritis: prevalence and associated features. J Clin Rheumatol. 2000;6:6-9.
22
Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA. 1991;266:3004-7.
23
Widawski L, Fabacher T, Spielmann L, et al. Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat. Clin Rheumatol. 2022;41:1421-9.
24
AlJohani R, Polachek A, Ye JY, Chandran V, Gladman DD. Characteristic and outcome of psoriatic arthritis patients with hyperuricemia. J Rheumatol. 2018;45:213-7.
25
Dominguez PL, Assarpour A, Kuo H, Holt EW, Tyler S, Qureshi AA. Development and pilot-testing of a psoriasis screening tool. Br J Dermatol. 2009;161:778-84.
26
Chen Z, Xu Y, Chen M, et al. Gout augments the risk of cardiovascular disease in patients with psoriasis: a population-based cohort study. Front Immunol. 2021;12:703119.
27
Oliviero F, Scanu A, Galozzi P, et al. Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Joint Bone Spine. 2013;80:287-90.
28
Galozzi P, Oliviero F, Frallonardo P, et al. The prevalence of monosodium urate and calcium pyrophosphate crystals in synovial fluid from wrist and finger joints. Rheumatol Int. 2016;36:443-6.
29
Galozzi P, Oliviero F, Scanu A, et al. Acute joint swelling in psoriatic arthritis: flare or “psout”-a 10-year-monocentric study on synovial fluid. Exp Biol Med (Maywood). 2022;247:1650-6.
30
Geneva-Popova M, Popova-Belova S, Popova V, Stoilov N. Assessment of crystals in the synovial fluid of psoriatic arthritis patients in relation to disease activity. Diagnostics (Basel, Switzerland). 2022;12.
31
Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the united states and decadal trends: the national health and nutrition examination survey, 2007-2016. Arthritis Rheumatol (Hoboken, NJ). 2019;71:991-9.
32
Moukarzel V, Doussière M, Barbier V, et al. Interest in daily clinical practice of screening for gouty disease in patients with psoriatic arthritis. Rheumatol Adv Pract. 2024;8:rkae069.
33
Ory PA, Gladman DD, Mease PJ. Psoriatic arthritis and imaging. Ann Rheum Dis. 2005;64(Suppl 2):ii55-7.
34
Stewart S, Dalbeth N, Vandal AC, Allen B, Miranda R, Rome K. Are ultrasound features at the first metatarsophalangeal joint associated with clinically-assessed pain and function? A study of people with gout, asymptomatic hyperuricaemia and normouricaemia. J Foot Ankle Res. 2017;10:22.
35
Breuer GS, Bogot N, Nesher G. Dual-energy computed tomography as a diagnostic tool for gout during intercritical periods. Int J Rheum Dis. 2016;19:1337-41.
36
Hu H-J, Liao M-Y, Xu L-Y. Clinical utility of dual-energy CT for gout diagnosis. Clin Imaging. 2015;39:880-5.
37
Tsai Y-G, Chang D-M, Kuo S-Y, Wang W-M, Chen Y-C, Lai J-H. Relationship between human lymphocyte antigen-B27 and clinical features of psoriatic arthritis. J Microbiol Immunol Infect. 2003;36:101-4.
38
Polachek A, Touma Z, Anderson M, Eder L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2017;69:67-74.
39
Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int. 2021;41:275-84.
40
Kwon HH, Kwon IH, Choi JW, Youn JI. Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. Clin Exp Dermatol. 2011;36:473-8.
41
Wu C, He C, Wang H, Wang W, Jin H. Impact of IL-17A inhibitors on serum uric acid levels in psoriatic patients with hyperuricemia: a prospective observational study. Psoriasis (Auckland, NZ). 2024;14:153-66.
42
Felten R, Widawski L, Spielmann L, et al. Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2-5 and MAXIMISE studies. RMD Open. 2023;9.
43
Luis-Rodríguez D, Donate-Correa J, Martín-Núñez E, et al. Serum urate is related to subclinical inflammation in asymptomatic hyperuricaemia. Rheumatology (Oxford). 2021;60:371-9.
44
Huang Y-Y, Ye Z, Gu S-W, Jiang Z-Y, Zhao L. The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout. J Int Med Res. 2020;48:300060520902950.
45
Hao G, Duan W, Sun J, Liu J, Peng B. Effects of febuxostat on serum cytokines IL-1, IL-4, IL-6, IL-8, TNF-α and COX-2. Exp Ther Med. 2019;17:812-6.
46
Arida D, Silva L, Skare TL. The hypouricemiant effect of leflunomide. Jt. bone spine. France; 2014. p. 273-4.
